Home » Market News » DirectorsTalk Highlights » Parkinson’s patients to receive cannabis oil in ‘pioneering’ trial to test drug’s effectiveness

Parkinson’s patients to receive cannabis oil in ‘pioneering’ trial to test drug’s effectiveness

Parkinson’s patients will receive cannabis oil in a “pioneering” clinical trial that aims to demonstrate the benefits, safety and efficacy of the treatment to help with hallucinations and delusions, two frightening symptoms of the disease.

Parkinson’s UK said the trial is particularly important as an increasing number of people are using expensive and unregulated cannabis oil, or CBD, supplements that have not been monitored for their effectiveness. The charity is partnering with King’s College London and investing £1.2m in the trial.

Sativa Group PLC (NEX:SATI) is a seed to consumer medicinal cannabis and cannabidiol (CBD) wellness business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.